Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Stock analysts at Jefferies Group increased their FY2018 EPS estimates for Ultragenyx Pharmaceutical in a research report issued to clients and investors on Wednesday. Jefferies Group analyst M. Raycroft now expects that the biopharmaceutical company will earn ($6.41) per share for the year, up from their previous forecast of ($6.43). Jefferies Group currently has a “Hold” rating and a $62.00 target price on the stock. Jefferies Group also issued estimates for Ultragenyx Pharmaceutical’s FY2019 earnings at ($5.86) EPS, FY2020 earnings at ($4.20) EPS and FY2021 earnings at ($2.13) EPS.

Several other analysts also recently weighed in on the company. Zacks Investment Research downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Stifel Nicolaus restated a “buy” rating and set a $111.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 30th. Canaccord Genuity restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Monday, May 8th. Cowen and Company restated an “outperform” rating on shares of Ultragenyx Pharmaceutical in a research note on Thursday, June 29th. Finally, ValuEngine upgraded Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $74.82.

ILLEGAL ACTIVITY WARNING: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/08/27/fy2018-earnings-forecast-for-ultragenyx-pharmaceutical-inc-rare-issued-by-jefferies-group.html.

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at 51.40 on Friday. The stock’s market capitalization is $2.18 billion. Ultragenyx Pharmaceutical has a 52 week low of $50.49 and a 52 week high of $91.35. The company’s 50 day moving average price is $63.00 and its 200-day moving average price is $66.10.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.73) by $0.01. During the same period in the previous year, the firm earned ($1.46) EPS.

A number of institutional investors have recently bought and sold shares of RARE. Fortaleza Asset Management Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 148.5% in the first quarter. Fortaleza Asset Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock worth $111,000 after buying an additional 980 shares in the last quarter. Sei Investments Co. acquired a new position in shares of Ultragenyx Pharmaceutical during the second quarter worth about $125,000. Pacer Advisors Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 22.6% in the first quarter. Pacer Advisors Inc. now owns 3,037 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 560 shares in the last quarter. Strs Ohio boosted its position in shares of Ultragenyx Pharmaceutical by 10.7% in the first quarter. Strs Ohio now owns 3,100 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 300 shares in the last quarter. Finally, Tocqueville Asset Management L.P. boosted its position in shares of Ultragenyx Pharmaceutical by 8.0% in the second quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 250 shares in the last quarter. Institutional investors and hedge funds own 95.71% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Stock Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.